Biosimilar Interchangeability Policies Need Closer Alignment
Executive Summary
Regulators should take more of a role in decisions on biosimilar switching and substitution, and international interchangeability practices should be brought into line, delegates at Medicines for Europe’s recent biosimilars conference heard.